Materiality asks whether an investor would want to know. Whether patients are harmed is a different question.
A global shutdown days after detection. From outside it reads as catastrophe; inside an incident it is often the correct call.
Generic manufacturing runs at high utilisation with no buffer stock. There is nothing in reserve when a plant stops.
Trial volunteers consented explicitly and specifically. The consent given did not contemplate this.
The unrecorded categories include a medicine arriving later than it would have.
It asks whether a record is trustworthy, not whether an adversary could reach the system holding it.
Real, distributed across people who will never know, and deferred by years. No instrument here can see it.
Two incidents among four operators is a strong signal. Two among several thousand is close to nothing.
Data integrity rules exist because a falsified batch record is a patient safety issue — and they describe exactly what an attacker would need to alter.
On every register in this corpus, the incident that mattered most did not happen.
A CRO holds unpublished, market-moving results for competing sponsors simultaneously, and no register would record their exposure.
The other fields require expertise to read. Participation in a trial for a named condition does not.
There is nothing else to say to an affected participant. That is the finding, not the criticism.
A compound in development represents a decade of investment, and its status is material information that is not yet public.
Item 1.05 does not ask whether a ransom was paid. So the largest extortion payment on record is compatible with a filing that never mentions one.
Pharma is permitted. Dentists are permitted. The line falls where a death could be attributed.